Latest Regulatory Progress News

Avecho Biotechnology has expanded its pivotal Phase III clinical trial for a CBD insomnia treatment by adding new recruitment sites and partnering with pharmaceutical giant Sandoz to boost patient enrolment and regulatory progress.

Southern Palladium has secured Environmental Authorisation for its Bengwenyama PGM Project, a crucial step toward mining rights and project development. The company is also refining a phased, lower-capital approach to unlock value and improve financeability.

Core Lithium has doubled the Grants Ore Reserve by shifting to underground mining, lifting total Finniss Ore Reserves to 10.73 million tonnes at 1.29% lithium oxide. This update supports a robust 10-year mine plan with potential for extended operations.

Anteris Technologies has submitted its FDA Investigational Device Exemption for the pivotal PARADIGM Trial of its DurAVR heart valve and marked a milestone of 100 patients treated, while expanding manufacturing capacity amid rising R&D costs.

Marvel Gold Limited has made significant progress in acquiring the Hanang Gold Project in Tanzania, submitting all regulatory documents and anticipating approvals soon. The company also prepares for its Annual General Meeting where shareholders will vote on a $2.5 million capital raising placement.

Patriot Battery Metals has announced a substantial upgrade to its Shaakichiuwaanaan Lithium Project, solidifying its position as the largest lithium pegmatite resource in the Americas and advancing its feasibility study on track for Q3 2025.

AVITA Medical reported a robust 67% increase in first quarter 2025 revenue, driven by new product launches and a strategic commercial overhaul, while reaffirming its full-year growth and profitability targets.

DMC Mining Limited has extended the closing date for its public share offer to August 2025 due to delays in securing exploration licences for its key Guinea projects. The company plans further regulatory updates to accommodate these changes.

Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.

Bio-Gene Technology Limited has raised $2.1 million through a placement and launched a Share Purchase Plan to fund critical safety studies for its flagship insecticide Flavocide®, alongside development of Qcide and strategic initiatives.

BlinkLab Limited has raised A$7.66 million through a well-supported placement to accelerate FDA regulatory trials for its autism and ADHD diagnostic platforms, leveraging its innovative smartphone-based technology.

Assetora Limited has dramatically reduced its net liabilities and strengthened its balance sheet through strategic capital raises and debt conversions, while unveiling a comprehensive rebrand and leadership expansion to drive its next growth phase.